Active Ingredient (Generic Name) | Nintedanib 150mg |
---|---|
Indication | Advanced or metastatic non-small cell lung cancer |
Manufacturer | Cipla Ltd |
Packaging | 1x10 |
Strength | 150 mg |
Delivery Time | 8 Days |
Nintib 150 mg Capsules (Nintedanib)
Nintib 150 mg Capsule contains Nintedanib, a tyrosine kinase inhibitor used in the treatment of Idiopathic Pulmonary Fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC) when used in combination with other therapies. It helps to slow down disease progression by inhibiting multiple growth factor receptors that are involved in lung tissue scarring and tumor growth.
Manufactured by Cipla, a trusted global pharmaceutical brand, Nintib is a cost-effective alternative to international brands such as Ofev, Vargatef, and Cyendiv.
Idiopathic Pulmonary Fibrosis (IPF)
Advanced or metastatic non-small cell lung cancer (NSCLC) (in combination therapy)
Nintedanib targets and inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR) involved in the processes of angiogenesis, fibrosis, and tumor proliferation, thereby slowing the progression of fibrotic lung disease and cancer.
Oral antifibrotic and anticancer medication
Convenient capsule form
Available in 3 x 10 capsule strips
Equivalent to branded drugs like Ofev (Boehringer Ingelheim)
Manufactured by Cipla Ltd, known for quality generics
Nintib 150 mg Capsules (Nintedanib)
Nintib 150 mg Capsule contains Nintedanib, a tyrosine kinase inhibitor used in the treatment of Idiopathic Pulmonary Fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC) when used in combination with other therapies. It helps to slow down disease progression by inhibiting multiple growth factor receptors that are involved in lung tissue scarring and tumor growth.
Manufactured by Cipla, a trusted global pharmaceutical brand, Nintib is a cost-effective alternative to international brands such as Ofev, Vargatef, and Cyendiv.
Idiopathic Pulmonary Fibrosis (IPF)
Advanced or metastatic non-small cell lung cancer (NSCLC) (in combination therapy)
Nintedanib targets and inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR) involved in the processes of angiogenesis, fibrosis, and tumor proliferation, thereby slowing the progression of fibrotic lung disease and cancer.
Oral antifibrotic and anticancer medication
Convenient capsule form
Available in 3 x 10 capsule strips
Equivalent to branded drugs like Ofev (Boehringer Ingelheim)
Manufactured by Cipla Ltd, known for quality generics